We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Gilead Sciences (GILD - Free Report) is expected to reveal quarterly earnings of $1.89 per share, indicating an increase of 4.4% compared to the year-ago period. Analysts forecast revenues of $6.89 billion, representing an increase of 3.4% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Gilead metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Total product sales- Total' should come in at $6.83 billion. The estimate points to a change of +3.4% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Royalty contract and other revenues' at $42.52 million. The estimate indicates a year-over-year change of -21.3%.
The combined assessment of analysts suggests that 'Product Sales- Liver Disease- Vemlidy- Total' will likely reach $221.37 million. The estimate indicates a change of -12.2% from the prior-year quarter.
Analysts predict that the 'Product Sales- Oncology- Cell Therapy- Yescarta- Total' will reach $364.23 million. The estimate indicates a change of -5.6% from the prior-year quarter.
Analysts expect 'Product Sales- HIV- Biktarvy- U.S.' to come in at $2.56 billion. The estimate indicates a year-over-year change of +3.3%.
It is projected by analysts that the 'Product Sales- HIV- Symtuza-Revenue share- U.S.' will reach $76.93 million. The estimate points to a change of -6.2% from the year-ago quarter.
Analysts forecast 'Product Sales- Oncology- Cell Therapy- Yescarta- U.S.' to reach $145.58 million. The estimate indicates a change of -9% from the prior-year quarter.
The consensus estimate for 'Product Sales- HIV- Odefsey- U.S.' stands at $193.64 million. The estimate indicates a change of -9.9% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Product Sales- Total HIV- U.S.' of $3.88 billion. The estimate points to a change of +6% from the year-ago quarter.
Analysts' assessment points toward 'Product Sales- Other- Other- U.S.' reaching $29.84 million. The estimate suggests a change of -36.5% year over year.
The consensus among analysts is that 'Product Sales- Oncology- Cell Therapy- Tecartus- U.S.' will reach $34.12 million. The estimate indicates a change of -14.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales- Liver Disease- Other Liver Disease- U.S.' should arrive at $157.80 million. The estimate suggests a change of +132.1% year over year.
Shares of Gilead have experienced a change of -5.8% in the past month compared to the +10% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GILD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
The upcoming report from Gilead Sciences (GILD - Free Report) is expected to reveal quarterly earnings of $1.89 per share, indicating an increase of 4.4% compared to the year-ago period. Analysts forecast revenues of $6.89 billion, representing an increase of 3.4% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Gilead metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Total product sales- Total' should come in at $6.83 billion. The estimate points to a change of +3.4% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Royalty contract and other revenues' at $42.52 million. The estimate indicates a year-over-year change of -21.3%.
The combined assessment of analysts suggests that 'Product Sales- Liver Disease- Vemlidy- Total' will likely reach $221.37 million. The estimate indicates a change of -12.2% from the prior-year quarter.
Analysts predict that the 'Product Sales- Oncology- Cell Therapy- Yescarta- Total' will reach $364.23 million. The estimate indicates a change of -5.6% from the prior-year quarter.
Analysts expect 'Product Sales- HIV- Biktarvy- U.S.' to come in at $2.56 billion. The estimate indicates a year-over-year change of +3.3%.
It is projected by analysts that the 'Product Sales- HIV- Symtuza-Revenue share- U.S.' will reach $76.93 million. The estimate points to a change of -6.2% from the year-ago quarter.
Analysts forecast 'Product Sales- Oncology- Cell Therapy- Yescarta- U.S.' to reach $145.58 million. The estimate indicates a change of -9% from the prior-year quarter.
The consensus estimate for 'Product Sales- HIV- Odefsey- U.S.' stands at $193.64 million. The estimate indicates a change of -9.9% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Product Sales- Total HIV- U.S.' of $3.88 billion. The estimate points to a change of +6% from the year-ago quarter.
Analysts' assessment points toward 'Product Sales- Other- Other- U.S.' reaching $29.84 million. The estimate suggests a change of -36.5% year over year.
The consensus among analysts is that 'Product Sales- Oncology- Cell Therapy- Tecartus- U.S.' will reach $34.12 million. The estimate indicates a change of -14.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales- Liver Disease- Other Liver Disease- U.S.' should arrive at $157.80 million. The estimate suggests a change of +132.1% year over year.
View all Key Company Metrics for Gilead here>>>Shares of Gilead have experienced a change of -5.8% in the past month compared to the +10% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GILD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .